Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.50 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975838 | 0.88 | HDAC1 (0.47) | RORCHDAC1HDAC8HDAC6 | |
| SCHEMBL4975832 | 0.88 | HDAC1 (0.47) | RORCHDAC1HDAC8HDAC6 | |
| SCHEMBL29661999 | 0.86 | TACR1 (0.57) | TACR1NPY5RGHSR | |
| SCHEMBL8067334 | 0.86 | TACR1 (0.57) | TACR1NPY5RGHSR | |
| SCHEMBL20955073 | 0.82 | XIAP (0.44) | TACR1RORCHDAC1HDAC8HDAC6 | |
| SCHEMBL2878354 | 0.81 | TACR1 (0.68) | TACR1HDAC1HDAC8HDAC6NPY5R | |
| SCHEMBL29661957 | 0.77 | RORC (0.46) | TACR1RORCHDAC1HDAC8HDAC6 | |
| SCHEMBL2625791 | 0.77 | HDAC1 (0.50) | TACR1RORCHDAC1HDAC8HDAC6 | |
| SCHEMBL4974614 | 0.77 | HDAC1 (0.50) | TACR1RORCHDAC1HDAC8HDAC6 | |
| SCHEMBL20955513 | 0.76 | HDAC1 (0.45) | RORCHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716504-A | Growth hormone secretagogue derivative and preparation method thereof | 上海拓界生物医药科技有限公司 | 2022-07-08 | — | — | CN | disclosed |